Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Bill journey · stage 4 of 5
On the President's desk
What it doesSummary reported to house (Jul 9, 2026)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
What just happenedOct 26, 2026
Presented to President.
Who’s behind it
- Placed on Calendar SenateJul 23, 2026
- Engrossed in HouseJul 22, 2026
- Reported in HouseJul 9, 2026
- Introduced in HouseApr 6, 2026
- Jul 23, 2026Calendars
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026FloorH38310
Motion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026FloorH37300
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Floor8000
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026FloorH30000
Considered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026FloorH37210
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 20, 2026FloorH8D000
DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026FloorH30000
Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
- Jul 20, 2026FloorH30300
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 9, 2026CalendarsH12410
Placed on the Union Calendar, Calendar No. 637.
- Jul 9, 2026CommitteeH12200
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Energy and Commerce Committee - Jul 9, 2026Committee5000
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Energy and Commerce Committee - May 21, 2026Committee
Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
Energy and Commerce Committee - May 21, 2026Committee
Committee Consideration and Mark-up Session Held
Energy and Commerce Committee - May 13, 2026Committee
Forwarded by Subcommittee to Full Committee by Voice Vote.
Health Subcommittee - May 13, 2026Committee
Subcommittee Consideration and Mark-up Session Held
Health Subcommittee - Apr 6, 2026Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 6, 2026IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Apr 6, 2026IntroReferralIntro-H
Introduced in House
- Apr 6, 2026IntroReferral1000
Introduced in House